MarkKirschbaumMD

PubMed

• 3 citations
  A phase II study of vascular endothelial growth factor trap (Aflibercept, NSC 724770) in patients with myelodysplastic syndrome: a California Cancer Consortium Study
  Mark Kirschbaum, Paul Frankel, Timothy W. Synold, Jasmine Zain, David F. Claxton, Joseph Tuscano, Edward M. Newman, David R. Gandara, Primo N. Lara> ;British Journal of Haematology. 2018 Feb 1
• 6 citations
  A phase I pharmacodynamic study of GTI-2040, an antisense oligonucleotide against ribonuclotide reductase, in acute leukemias: a California Cancer Consortium study
  Mark Kirschbaum, Paul Frankel, Timothy W. Synold, Zhiliang Xie, Yun Yen, Leslie Popplewell, Robert T. Chen, Omar S. Aljitawi, Joseph Tuscano, Kenneth K. Chan, Edward M...> ;Leukemia & Lymphoma. 2016 Feb 19
• 227 citations
  Results of the phase i trial of RG7112, a small-molecule MDM2 antagonist in leukemia
  Michael Andreeff, Kevin R. Kelly, Karen W.L. Yee, Sarit Assouline, Roger Strair, Leslie Popplewell, David G. Bowen, Giovanni Martinelli, Mark Drummond, Paresh Vyas, Ma...> ;Clinical Cancer Research. 2016 Feb 15
• 41 citations
  Romidepsin in peripheral and cutaneous T‐cell lymphoma: mechanistic implications from clinical and correlative data
  Susan E. Bates, Robin Eisch, Alexander Ling, Douglas R. Rosing, Maria L. Turner, Stefania Pittaluga, H. Miles Prince, Mark Kirschbaum, Steven L. Allen, Jasmine Zain, L...> ;British Journal of Haematology. 2015 Jul 1
• 57 citations
  A phase II study of vorinostat and rituximab for treatment of newly diagnosed and relapsed/refractory indolent non-Hodgkin lymphoma
  Robert T. Chen, Paul Frankel, Leslie Popplewell, Tanya Siddiqi, Nora Ruel, Arnold J. Rotter, Sandra H. Thomas, Michelle Mott, Nitya Nathwani, Myo Htut, Auayporn Nadema...> ;Haematologica. 2015 Mar 1
• 102 citations
  A phase 1 clinical trial of vorinostat in combination with decitabine in patients with acute myeloid leukaemia or myelodysplastic syndrome
  Mark Kirschbaum, Ivana Gojo, Stuart L. Goldberg, Christopher Bredeson, Lisa Kujawski, Allen S. Yang, Peter W. Marks, Paul Frankel, Xing Sun, Alessandra Tosolini, Josep...> ;British Journal of Haematology. 2014 Oct 1
• 51 citations
  Immune regulatory effects of panobinostat in patients with Hodgkin lymphoma through modulation of serum cytokine levels and T-cell PD1 expression.
  Y. Oki, Daniela Buglio, Jianhua Zhang, Y. Ying, Shouhao Zhou, Anna Sureda, Dina Ben-Yehuda, Pier Luigi Zinzani, Henry Miles Prince, Simon J. Harrison, Mark Kirschbaum,...> ;Blood Cancer Journal. 2014 Aug 8
• 17 citations
  Four different regimens of farnesyltransferase inhibitor tipifarnib in older, untreated acute myeloid leukemia patients: North American Intergroup Phase II study SWOG ...
  Harry P. Erba, Megan Othus, Roland B. Walter, Mark Kirschbaum, Martin S. Tallman, Richard A. Larson, Marilyn L. Slovak, Kenneth J. Kopecky, Holly Gundacker, Frederick ...> ;Leukemia Research. 2014 Mar 1
• 53 citations
  A phase 2 study of belinostat (PXD101) in patients with relapsed or refractory acute myeloid leukemia or patients over the age of 60 with newly diagnosed acute myeloid...
  Mark Kirschbaum, Kenneth A. Foon, Paul Frankel, Christopher Ruel, Bernadette Pulone, Joseph Tuscano, Edward M. Newman> ;Leukemia & Lymphoma. 2014 Feb 24
• 90 citations
  Phase II Study of the Oral MEK Inhibitor Selumetinib in Advanced Acute Myelogenous Leukemia: A University of Chicago Phase II Consortium Trial
  Nitin Jain, Emily Curran, Neil M. Iyengar, Ernesto Diaz-Flores, Rangesh Kunnavakkam, Leslie Popplewell, Mark Kirschbaum, Theodore Karrison, Harry P. Erba, Margaret Gre...> ;Clinical Cancer Research. 2014 Jan 15
• 46 citations
  SIRT1 activation enhances HDAC inhibition-mediated upregulation of GADD45G by repressing the binding of NF-κB/STAT3 complex to its promoter in malignant lymphoid cells
  Anna Scuto, Mark Kirschbaum, Ralf Buettner, Maciej Kujawski, J M Cermak, Peter Atadja, Richard Jove> ;Cell Death & Disease. 2013 May 16
• 209 citations
  Panobinostat in Patients With Relapsed/Refractory Hodgkin's Lymphoma After Autologous Stem-Cell Transplantation: Results of a Phase II Study
  Anas Younes, Anna Sureda, Dina Ben-Yehuda, Pier Luigi Zinzani, Tee Chuan Ong, H. Miles Prince, Simon J. Harrison, Mark Kirschbaum, Patrick B. Johnston, Jennifer Gallag...> ;Journal of Clinical Oncology. 2012 Apr 30
• 20 citations
  A phase I study in adults of clofarabine combined with high-dose melphalan as reduced-intensity conditioning for allogeneic transplantation.
  Mark Kirschbaum, Anthony S. Stein, Leslie Popplewell, Maria Delioukina, Robert T. Chen, Ryotaro Nakamura, David S. Snyder, Joel Conrad, Simon F. Lacey, Paul Frankel, A...> ;Biology of Blood and Marrow Transplantation. 2012 Mar 1
• 59 citations
  A phase 2 study of vorinostat for treatment of relapsed or refractory Hodgkin lymphoma: Southwest Oncology Group Study S0517.
  Mark Kirschbaum, Bryan Goldman, Jasmine Zain, James R. Cook, Lisa M. Rimsza, Stephen J. Forman, Richard I. Fisher> ;Leukemia & Lymphoma. 2012 Feb 1
• 2 citations
  Histone deacetylase inhibitors and Hodgkin's lymphoma
  Mark Kirschbaum> ;The Lancet. Oncology. 2011 Dec 1
• 363 citations
  Phase 2 trial of romidepsin in patients with peripheral T-cell lymphoma
  Richard Piekarz, Robin Frye, H. Miles Prince, Mark Kirschbaum, Jasmine Zain, Steven L. Allen, Elaine S. Jaffe, Alexander Ling, Maria L. Turner, Cody J. Peer, William D...> ;Blood. 2011 Jun 2
• 84 citations
  Combining Histone Deacetylase Inhibitor Vorinostat with Aurora Kinase Inhibitors Enhances Lymphoma Cell Killing with Repression of c-Myc, hTERT, and microRNA Levels
  Leo Kretzner, Anna Scuto, Pamela M. Dino, Claudia M. Kowolik, Jun Wu, Patrick E. Ventura, Richard Jove, Stephen J. Forman, Yun Yen, Mark Kirschbaum> ;Cancer Research. 2011 Jun 1
• 16 citations
  A phase 1 trial dose-escalation study of tipifarnib on a week-on, week-off schedule in relapsed, refractory or high-risk myeloid leukemia
  Mark Kirschbaum, Timothy W. Synold, Anthony S. Stein, Joseph Tuscano, Jasmine Zain, Leslie Popplewell, Chatchada Karanes, Margaret R. O'Donnell, Bernadette Pulone, Ama...> ;Leukemia. 2011 May 31
• Phase I/II trial of the MEK1/2 inhibitor GSK1120212 (GSK212) in patients (pts) with relapsed/refractory myeloid malignancies: Evidence of activity in pts with RAS muta...
  Borthakur G, Popplewell L, Kirschbaum MH, Foran JM, Kadia TM, Jabbour E, Boyiadzis M, Verma A, Walter RB, Wissel PS, Xu L, Bauman JW, Zhu JZ, Mazumdar J, Baccus M, Con...> ;J. Clin. Oncol.. 2011-05-20
• 156 citations
  Phase II Study of Vorinostat for Treatment of Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma and Mantle Cell Lymphoma
  Mark Kirschbaum, Paul Frankel, Leslie Popplewell, Jasmine Zain, Maria Delioukina, Vinod Pullarkat, Deron Matsuoka, Bernadette Pulone, Arnold J. Rotter, Igor Espinoza-D...> ;Journal of Clinical Oncology. 2011 Mar 20
• Comeback for the camptothecins
  Mark Kirschbaum> ;Leukemia & Lymphoma. 2009 Dec 9
• 535 citations
  Phase II Multi-Institutional Trial of the Histone Deacetylase Inhibitor Romidepsin As Monotherapy for Patients With Cutaneous T-Cell Lymphoma
  Richard Piekarz, Robin Frye, Maria L. Turner, John Wright, Steven L. Allen, Mark Kirschbaum, Jasmine Zain, H. Miles Prince, John P. Leonard, Larisa J. Geskin, Craig B....> ;Journal of Clinical Oncology. 2009 Nov 10
• 78 citations
  Sorafenib inhibits signal transducer and activator of transcription 3 signaling associated with growth arrest and apoptosis of medulloblastomas.
  Fan Yang, Timothy E. Van Meter, Ralf Buettner, Michael Hedvat, Wei Liang, Claudia M. Kowolik, Nilesh Mepani, Janni Mirosevich, Sangkil Nam, Mike Y. Chen, Gary W. Tye, ...> ;Molecular Cancer Therapeutics. 2008 Nov 1
• 1 citations
  hENT1 and Hodgkin lymphoma: not just crossing the channel.
  Mark Kirschbaum> ;Leukemia & Lymphoma. 2008 Jun 1
• 74 citations
  HDAC inhibitor reduces cytokine storm and facilitates induction of chimerism that reverses lupus in anti-CD3 conditioning regimen
  Nainong Li, Dongchang Zhao, Mark Kirschbaum, Chunyan Zhang, Chia-Lei Lin, Ivan Todorov, Fouad Kandeel, Stephen J. Forman, Defu Zeng> ;Proceedings of the National Academy of Sciences of the United States of America. 2008 Mar 25
• Join now to see all